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Risk-adaptive therapy forHodgkin’s lymphomafocuses ontreatment modiﬁcationsbased onassessmentofresponse.[18F]Fluoro-
deoxyglucose positron emissiontomography(PET) performed during or after completion of chemotherapy is a strong prognostic
factor for eventual treatment outcome. Conceptually, this strategy seeks to increase eﬃcacy and minimize toxicity through the
appropriate selection of patients for either therapy escalation (high-risk, PET positive) or de-escalation (low-risk, PET negative).
Preliminary evidence with tailoring both chemotherapy (drug selection, number of cycles, and dose) and radiotherapy (omission
or inclusion)is varied; however, numerous clinical trials seeking to validate this approach are ongoing.This paper summarizes the
available evidence and active protocols involving PET response-adapted therapy for adult (early and advanced stages) Hodgkin’s
lymphoma.
1.Introduction
Treatment of Hodgkin’s lymphoma (HL) with modern com-
bination chemotherapy and radiation therapy has increased
long-term survival to greater than 75% [1]. In the United
States, most patients receive a chemotherapy backbone
consisting of ABVD (doxorubicin, bleomycin, vinblastine,
dacarbazine) with or without consolidative involved-ﬁeld
radiotherapy (IFRT) [2]. Eﬀorts to improve outcomes in
advanced-stage disease have lead to development of intensi-
ﬁed chemotherapy regimens such as BEACOPP (bleomycin,
etoposide, doxorubicin, cyclophosphamide, vincristine, pro-
carbazine, prednisone), but there is concern for increased
risk of hematologic side eﬀects and acute leukemia [3].
Consolidative IFRT following chemotherapy for advanced
stage disease may be included as part of certain treatment
regimens [4, 5]. Stanford V (abbreviated, dose-intense)
chemotherapy with IFRT has yielded promising results in a
phase II trial, with results from an intergroup trial (ECOG-
2496) comparing Stanford V and ABVD awaited [6].
In an eﬀort to tailor treatment towards both favor-
able and unfavorable-risk patients, response-adaptive ther-
apy involves modiﬁcations (de-escalation or intensiﬁcation,
resp.) based upon response assessment. The prognostic value
of PET, both during and after completion of treatment, has
been demonstrated [7]. As a result, there has been active
interestindevelopingprotocolswhich combineconventional
stratiﬁcation (stage, bulky disease, adverse prognostic fac-
tors) with assessment ofPET response. This review will focus
on describing both the preliminary evidence regarding PET-
adaptive therapy as well as the mechanisms (chemotherapy
and radiotherapy modiﬁcations) being investigated in ongo-
ing clinical trials.
2.Prognostic ValueofEarlyInterim
PET Response
Studies in high-grade non-Hodgkin’s lymphoma, with the
inclusion of a few HL patients, ﬁrst demonstrated a strong
predictive value of PET scan performed after 1-2 cycles
of chemotherapy [8–10]. In a subsequent analysis of 85
patients with HL, Hutchings identiﬁed PET response after
two or three cycles of chemotherapy to be an accurate and
independentpredictorofprogression-free survival(PFS)and
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scans suﬀered disease relapse within 2 years. Furthermore,
patients classiﬁed at the time as having “minimal residual
uptake” on PET behaved similarly to PET-negative patients,
suggesting the consideration of this ﬁnding as a PET
complete response (CR) [11].
In a Danish prospective analysis, 77 patients with HL
of all stages (63% Stage I/II) were treated with ABVD
chemotherapy and IFRT as per institutional protocols. PET
was performed after two cycles (PET-2) of chemotherapy;
however, no treatment modiﬁcation was made based on
PET response. With 11 out of 16 (69%) PET-2-positive
patients relapsing or progressing, compared to just 3 out
of 61 (5%) PET-2-negative patients, PET-2 response was
found to be a signiﬁcant predictor for both PFS and OS
(P<. 01). PET-2 response was the strongest predictor of
PFS on multivariate analysis, and PET was proved superior
to conventional computer tomography (CT) imaging [12].
An Italian prospective trial examined PET-2 response in
108 patients (mostly advanced stage) treated with ABVD
with 54% receiving IFRT. PET-2 response correctly predicted
treatment outcome in 95% of patients, with a positive
predictive value of 90% and a negative predictive value of
97% [13].
In a combined analysis of the Italian and Danish
prospective trials, the 2-year PFS was 12.8% for PET-2-
positive patients compared to 95.0% if PET-2 negative (P<
.001). PET-2 response was the only signiﬁcant predictor of
outcome on multivariate analysis (P<. 0001). Both the
negative predictivevalue(NPV)and positive predictivevalue
(PPV) of PET-2 response were excellent (92% and 93%,
resp.) [14]. In a systematic review involving 360 patients
with advanced-stage HL, interim PET/CT had an overall
sensitivity of 81% and speciﬁcity of 97% [15]. It should be
emphasized that this analysis reﬂects the prognostic value of
interim PET in patients continuing with planned treatment
regimens. These numerical values cannot be extrapolated to
predict outcomes if modiﬁcations are made, but do indicate
an overall good outcome following treatment in patient with
interim PET-CR.
3.ChemotherapyModiﬁcationBased on
PETResponse
One approach under investigation for early-interim PET-
negative patients, who have an improved prognosis, is to
employ chemotherapy reduction strategies. In advanced-
stage disease, where higher doses of chemotherapy are
indicated, omitting chemotherapy cyclesor changing to less-
intensive chemotherapy could potentially spare treatment-
related toxicity with the goal of maintaining eﬃcacy. The
major risk of treatment de-escalation, even following an
interim good response, is the potential for inferior out-
comes as a result of less-intensive therapy. In contrast for
patients found to be interim PET-positive, this may indicate
aggressive disease for which chemotherapy escalation would
be beneﬁcial. The early experience from two Israeli trials
employing chemotherapy modiﬁcation is reviewed below.
Investigators in Haifa, Israel, prospectively treated 108
HL patients (all stages) with an initial two cycles of escalated
BEACOPP (BEACOPPesc) or standard dose BEACOPP
chemotherapy based on pretreatment risk stratiﬁcation.
Subsequenttherapy was based onPET-2 response, with PET-
2-negative patients receiving standard BEACOPP and PET-
2-positive patients receiving BEACOPPesc (both 4 cycles).
Protocol indications for radiation therapy, given to 36%
of patients, included initial bulky disease (>10cm) and a
single PET-positive site after completing chemotherapy. Of
the 39 patients with initial high-risk disease (international
prognostic score, IPS > 3), 79% were PET-2 negative
after two cycles of escalated BEACOPP and subsequently
received 4 cycles of standard dose BEACOPP. Interim PET-
based treatment was eﬀective and feasible, with 5-year event-
free survival (EFS) and OS of 85% and 90%, respectively
[16].
In a phase II study of 43 patients, investigators at
Hadassah University Hospital, Jerusalem, treated advanced
stage HL (IPS > 3, bulky IIB, III, and IV) with 2 cycles of
escalated BEACOPP and then evaluated for PET response
[17]. Patients with a favorable PET response received an
additional 4 cycles of ABVD. Results of this study were
comparable to similar patients (high-risk, advanced HL)
treated in the German HD9 trial with 8 cycles BEACOPPesc.
Additionally, PET response was prognostic for treatment
outcome; the 4-year PFS for PET-2-negative patients was
87%, compared to 53% if PET-2 positive. The results
of these single-institution studies, involving relatively few
patients, do suggest feasibility with chemotherapy modiﬁ-
cation based on interim PET response. Applicability with
regard to less intensive ABVD chemotherapy, as compared
to the BEACOPP-based regimens employed, is unknown.
These data require validation in large clinical trials, which
are underway, before incorporation into general prac-
tice.
4.ConsolidativeRadiationTherapyBased on
PET Response
There remains continued interest in identifying which
patients may beneﬁt from consolidative IFRT following
systemic chemotherapy. PET response has been investigated
in this regard as well. As with chemotherapy treatment
modiﬁcation, there is potential for over-treatment (PET
false positive) as well as the risk of inferior outcome
with omission of IFRT (PET false negative). Early studies
utilizing this approach, summarized below, are varied with
regard to outcomes, early-versus late-stage patients, and
chemotherapy regimens employed.
In an analysis of 81 patients (72% early stage) treated
with Stanford V chemotherapy and IFRT, PET positive
patients after completion of chemotherapy did signiﬁcantly
worse than PET negative patients (FFP33% versus FFP96%,
resp. P<. 0003). IFRT (20 to 30Gy) was given to all patients
and sites of relapse included ﬁelds treated by radiotherapy
for all patients with recurrence. Thus, in patients with PET-
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with low-dose IFRT is likely inadequate [18]. In contrast,
researchers at Dana Farber Cancer Institute supported
the use of consolidative IFRT in PET-positive patients after
completion of 4 to 6 cycles of ABVD. While PET-positive
patients after chemotherapy did worse (2-year FFS 69%
compared to 95% PET negative, P<. 01), the authors
conclude that IFRT potentially cured a proportion of
patients with persistent PET-positive disease following
ABVD [19]. Conclusions from this study are limited due
to its retrospective nature, and therefore the eﬀect of low-
dose IFRT following ABVD (for both PET-positive and
PET-negative patients) is diﬃcult to ascertain.
Within the HD15 trial of the German Hodgkin Study
Group (GHSG), 817 patients (stage IIB bulky/extranodal,
III, IV) were randomized to three variations of BEACOPP
chemotherapy and assessed for response by PET-CT at
completion (6 to 8 cycles). Patients with PET-positive
residual disease (>2.5cm in size) received 30Gy IFRT. The
PFS for patients with PET-negative residues (treated with
chemotherapy alone) was 96% compared to 86% for PET-
positive patients treated with chemotherapy and IFRT (P =
.011). While these data are preliminary, patients with a PET-
CR after 6–8 cycles of BEACOPP chemotherapy were spared
radiotherapy with no impact on early progression or relapse
[20]. In the only published randomization evaluating IFRT
based on PET response, investigators in Naples, Italy, treated
260 patients with bulky HL (>5cm, all stages) with VE-BEP
(vinblastine, etoposide, bleomycin, epirubicin, prednisone)
chemotherapy for six cycles and assessed PET response.
Patients with a PET CR after completion of chemotherapy
were randomized to treatment with or without IFRT (32Gy
to initial bulky disease and contiguous nodal regions).
Patients treated with chemotherapy alone, even after a PET
CR, did worse (EFS 86% compared to 96% with IFRT,
P = .03). Additionally, all relapses in patients treated
without radiotherapy occurred in sites where IFRT would
have been given. Of the patients with PET-positive disease
after chemotherapy (treated with high-dose chemotherapy
and stem cell transplant), 50% were alive and disease-
free. The authors concluded that even after a PET CR,
I F R Tc a ni m p r o v eE F Si np a t i e n t s with initial bulky disease
[21].
Overall, the data regarding PET response-guided radio-
therapy are conﬂicting, therefore it is too soon to draw
reliable conclusions regarding the inclusion of radiotherapy
based on PET CR. The most reliable data, from the GHSG
HD15 trial, suggest that it is safe to omit RT following
intensive BEACOPP chemotherapy (not commonly used
in the US). Retrospective data conﬁrm that with PET-
positive residues following chemotherapy (ABVD or Stan-
ford V), these patients have a poor prognosis and therefore
more aggressive disease. Furtherc l i n i c a lt r i a l ss h o u l dg i v e
insight to whether further chemotherapy, IFRT,or high-dose
chemotherapy with stem cell rescue should be employed
in these patients. Additionally, no data exist regarding the
impact of interim PET-2 response on the inclusion of IFRT
and techniques employing these strategies are ongoing and
summarized below.
5.ActiveTrials:AdultEarlyStageHL
PET-based protocols for early-stage HL are currently eval-
uating the inclusion of IFRT only if PET-2 positive, as well
as intensifying chemotherapy in these patients. CALGB trials
50604 and 50801 (non bulky and bulky Stage I/II, resp.)
assess for PET response after an initial 2 cycles of ABVD
(clinicaltrials.gov ID NCT01132807 and NCT01118026,
resp.). Patients that are PET-2 negative receive ABVD alone
(4 cycles if non bulky, 6 cycles if bulky), with radiotherapy
omitted in these patients. PET-2-positive patients receive
additional BEACOPPesc (2 cycles if nonbulky, 4 cycles if
bulky) followed by consolidative IFRT (30.6Gy to initial
disease sites). The German HD16 for early-stage HL (favor-
able stage I/II) is testing 2 cycles of ABVD and 30Gy
IFRT compared to the same regimen with PET response-
guided radiotherapy. Patients on the ﬁrst arm receive IFRT
regardless of PET-CT response, while patients on the second
arm receive IFRT only if PET-2 positive (clinicaltrials.gov ID
NCT00736320). The H10 EORTC/GELA study is recruiting
patients with stage I/II disease to ABVD 3-4 cycles and
30Gy INRT (involved node RT) versus PET-guided therapy.
In the comparator arm, PET-2-negative patients receive an
additional 2–4 courses ABVD only. PET-2-positive-patients
receive BEACOPPesc for 2 cycles and 30Gy INRT. As of July
2009, this trial had accrued 1,097 out of a planned 1,200
patients and the ﬁnal results of thisimportant trial is awaited
[22].
6.ActiveTrials:AdultAdvancedStageHL
For advanced stage HL, current protocols focus on chem-
otherapy escalation or reduction based on PET-2-response.
Trials from Cancer Research UK (stage IIB-IV) and South-
west Oncology Group (SWOG, stage III/IV) treat PET-2-
positivepatientsafterABVDwithBEACOPP-basedregimens
(NCT00678327 and NCT00822120, resp.). Chemotherapy
randomizations following PET-2-positive disease compare
BEACOPP-14 to BEACOPP-esc (SWOG) and BEACOPP to
BEACOPPesc(CancerResearchUK).PET-2negative patients
on the SWOG trial receive ABVD alone (4 additional
cycles), whereas on the Cancer Research UK trial they are
randomized tochemotherapyreduction(4cyclesABVversus
4c y c l e sA B V D ) .
To evaluate inclusion of radiotherapy based on PET
response, an Italian protocol (stage III/IV) randomizes
PET-2 negative patients to ABVD with or without IFRT
(NCT00784537). PET-2 positive patients receive high dose
chemotherapy and stem cell transplant. Based on favorable
resultsinpatientstreatedwith chemotherapyaloneafterPET
complete response on HD15, the German HD18 trial for
advanced/unfavorable HL (stage IIB, III, IV) includes radio-
therapyonlyforPET -positiveresides(>2.5cm)aftercomple-
tion of chemotherapy [clinicaltrials.gov ID NCT00515554].
This trial also tests randomizations for PET-2 negative
patients receiving BEACOPPesc chemotherapy (4 versus 8
total cycles) and PET-2 positive patients (8 total cycles with
or without rituximab).4 Advances in Hematology
7.Conclusions
PET response is strongly prognostic for treatment outcome
in HL. As a result, interest has developed in tailoring
treatment based upon PET assessment. While this approach
has the potential to identify appropriate patients for either
intensifying or deintensifying therapy, the mechanisms to
do so remain largely undeﬁned. Treatment de-escalation
strategies carry a risk of negatively impacting the overall
highly favorable outcomes in this disease. Likewise, there
is no consensus regarding the appropriate treatment of
PET-avid disease (interim or after completion of therapy),
in which these patients may require intensive therapy. An
active interest in PET response-based treatment strategies
is demonstrated through widespread incorporation into
Hodgkin’s lymphoma protocols, but the variety of strate-
gies being employed reﬂect a relative lack of experience
with this approach. The results of these upcoming studies
will hopefully answer the combined questions of whether
and how treatment can be safely modiﬁed based on
PET response.v
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